
    
      PD1 antibody is recommended for dMMR/MSI-H metastatic colorectal cancer patients as second
      line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also
      recommended as an alternative choice for unresectable locally advanced colon cancer. Thus,
      this phase II, single arm study will investigate the efficacy and toxicity of combination
      strategy using PD1 antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal
      cancer patients, which is expected to yield higher tumor regressiona with tolerable toxicity.
    
  